This biotech company develops novel oncolytic viral therapies, specifically engineered vectors, to target and treat aggressive cancers such as glioblastoma and metastatic melanoma. Their platform aims to provide more effective treatment options for difficult-to-treat cancers by leveraging a unique approach to viral oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Many aggressive cancers, such as glioblastoma and metastatic melanoma, are resistant to traditional treatments due to challenges in drug delivery, tumor heterogeneity, and an immunosuppressive tumor microenvironment. Current precision therapeutics often fail to provide effective solutions for these difficult-to-treat cancers.
Solution
U.P. Oncolytics is developing oncolytic viral therapies that harness the natural ability of viruses to selectively target and destroy cancer cells while stimulating an immune response. Their approach utilizes engineered viral vectors to overcome the limitations of conventional cancer treatments. By leveraging the specificity of oncolytic viruses, the platform aims to provide safe and effective treatments for cancers that are poorly responsive to existing therapies. The viruses attack cancer cells without regard to the diverse cellular changes within the tumor, offering a potential solution for heterogeneous cancers like glioblastoma.
Target Audience
The primary target audience includes patients with refractory and poorly responsive cancers like glioblastoma (GBM) and metastatic melanoma, as well as the physicians who treat them.
Features
- Engineered oncolytic viruses designed to selectively target and destroy cancer cells.
- Immunomodulatory capabilities to stimulate the patient's own immune system to fight the cancer.
- Focus on cancers resistant to traditional treatments, such as glioblastoma and metastatic melanoma.
- Viral vectors designed to overcome challenges in drug delivery and penetrate the tumor microenvironment.